A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer (CARRIE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02399137 |
Recruitment Status :
Completed
First Posted : March 26, 2015
Last Update Posted : September 18, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pancreatic Cancer | Drug: MM-141 Drug: Placebo Drug: Gemcitabine Drug: Nab-Paclitaxel | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 88 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer |
Study Start Date : | May 2015 |
Actual Primary Completion Date : | August 2018 |
Actual Study Completion Date : | August 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm A (Experimental Arm)
MM-141 in combination with nab-paclitaxel and gemcitabine
|
Drug: MM-141 Drug: Gemcitabine Other Name: Gemzar Drug: Nab-Paclitaxel Other Name: Abraxane |
Active Comparator: Arm B (Comparator Arm)
Placebo in combination with nab-paclitaxel and gemcitabine
|
Drug: Placebo Drug: Gemcitabine Other Name: Gemzar Drug: Nab-Paclitaxel Other Name: Abraxane |
No Intervention: Observational Group |
- Progression Free Survival [ Time Frame: Approximately 2 years ]
- Overall Survival [ Time Frame: Approximately 2.5 years ]
- Objective Response Rate according to RECIST v1.1 [ Time Frame: Approximately 2 years ]
- Duration of Response according to RECIST v1.1 [ Time Frame: Approximately 2 years ]
- Rate of adverse events reported with the combination of MM-141 with nab-paclitaxel and gemcitabine versus the comparator arm [ Time Frame: Approximately 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Metastatic adenocarcinoma of the pancreas. Patients with islet cell neoplasms are not eligible.
- Patient must have received no prior radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease.
- Blood sample sent for free IGF-1 testing
- ECOG performance status (PS) of 0 or 1
Exclusion Criteria:
- Patients who only present with localized disease
- Patients with CNS malignancies (primary or metastatic)
- Clinically significant cardiac disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02399137
Study Director: | MM-141 Medical Director, MD | Merrimack Pharmaceuticals |
Responsible Party: | Merrimack Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT02399137 |
Other Study ID Numbers: |
MM-141-07-02-02 |
First Posted: | March 26, 2015 Key Record Dates |
Last Update Posted: | September 18, 2018 |
Last Verified: | September 2018 |
Pancreatic Cancer Front-line Pancreatic Cancer Metastatic Pancreatic Cancer Gemcitabine |
Nab-paclitaxel Abraxane Free IGF-1 Heregulin |
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Paclitaxel |
Gemcitabine Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antimetabolites |